Posted by Michael Wonder on 03 Jan 2023
Hansa Biopharma announces positive reimbursement decision for Idefirix (imlifidase) in the Czech Republic
2 January 2023 - Idefirix is the first and only product approved for use in highly sensitised patients waiting for a kidney transplant in the Czech Republic.
Hansa Biopharma today announces that it has attained reimbursement in the Czech Republic for its first in class treatment, Idefirix, for the desensitisation treatment of highly sensitised adult patients prior to kidney transplant from a deceased donor.
